Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017
出版年份 2018 全文链接
标题
Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017
作者
关键词
-
出版物
Infectious Diseases
Volume 50, Issue 8, Pages 569-583
出版商
Informa UK Limited
发表日期
2018-03-02
DOI
10.1080/23744235.2018.1445281
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
- (2018) Tarik Asselah et al. Clinical Gastroenterology and Hepatology
- Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
- (2018) David Wyles et al. HEPATOLOGY
- IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir
- (2017) Thomas R. O’Brien et al. GASTROENTEROLOGY
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
- (2017) Ira M. Jacobson et al. GASTROENTEROLOGY
- The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection
- (2017) William F. Balistreri et al. HEPATOLOGY
- Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection
- (2017) Stefan Wirth et al. HEPATOLOGY
- Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection
- (2017) Kristofer Andréasson et al. JOURNAL OF HEPATOLOGY
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
- (2017) Paul Y. Kwo et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
- (2017) Reem Waziry et al. JOURNAL OF HEPATOLOGY
- Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
- (2017) Xavier Forns et al. LANCET INFECTIOUS DISEASES
- Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
- (2017) Edward Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
- (2017) Marc Bourlière et al. NEW ENGLAND JOURNAL OF MEDICINE
- PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C
- (2017) Janne Fuglsang Hansen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016
- (2017) Martin Lagging et al. Infectious Diseases
- Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
- (2016) Gregory J. Dore et al. ANNALS OF INTERNAL MEDICINE
- Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
- (2016) Paul Kwo et al. HEPATOLOGY
- Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)
- (2016) Eric Lawitz et al. HEPATOLOGY
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
- (2016) María Reig et al. JOURNAL OF HEPATOLOGY
- Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts
- (2016) JOURNAL OF HEPATOLOGY
- Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
- (2016) Jesper Waldenström et al. PLoS One
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
- (2015) Edward J. Gane et al. GASTROENTEROLOGY
- Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
- (2015) Eric Lawitz et al. GASTROENTEROLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis
- (2015) Hiromitsu Kumada et al. HEPATOLOGY
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
- (2015) K. Rajender Reddy et al. HEPATOLOGY
- Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1
- (2015) Mark S. Sulkowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection
- (2015) A. Abergel et al. JOURNAL OF HEPATOLOGY
- LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study
- (2015) P.J. Pockros et al. JOURNAL OF HEPATOLOGY
- Expanding consensus in portal hypertension
- (2015) Roberto de Franchis JOURNAL OF HEPATOLOGY
- Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
- (2015) Jacob Lalezari et al. JOURNAL OF HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2015
- (2015) JOURNAL OF HEPATOLOGY
- Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial
- (2015) M. Lagging et al. JOURNAL OF VIRAL HEPATITIS
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
- (2015) David Roth et al. LANCET
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
- (2015) Christophe Hézode et al. LANCET
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
- (2015) Marc Bourlière et al. LANCET INFECTIOUS DISEASES
- Ledipasvir–sofosbuvir for hepatitis C genotype 4 infection
- (2015) Michael A Smith et al. LANCET INFECTIOUS DISEASES
- Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
- (2015) Masashi Mizokami et al. LANCET INFECTIOUS DISEASES
- Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
- (2015) Anita Kohli et al. LANCET INFECTIOUS DISEASES
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
- (2015) Michael P. Curry et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) Susanna Naggie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) David L. Wyles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection
- (2015) Karolina Rembeck et al. PHARMACOGENOMICS
- Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
- (2015) Jesper Waldenström et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency
- (2015) Gregory L. Hundemer et al. Infectious Diseases
- Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs
- (2014) Massimo Puoti et al. DIGESTIVE AND LIVER DISEASE
- Do variations in the ITPA gene determine the risk of hepatitis C virus relapse?
- (2014) Jesper Waldenström et al. Future Microbiology
- Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3
- (2014) Karolina Rembeck et al. HEPATOLOGY
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis
- (2014) Magdalena Ydreborg et al. PLoS One
- A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis
- (2013) Soo Aleman et al. CLINICAL INFECTIOUS DISEASES
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C Infection
- (2013) Magdalena Ydreborg et al. PLoS One
- PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
- (2012) Karolina Rembeck et al. BMC Medical Genetics
- Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C
- (2012) Laurent Castera GASTROENTEROLOGY
- Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes
- (2012) Martin Lagging PHARMACOGENOMICS
- Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3
- (2012) Karolina Rembeck et al. PLoS One
- Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children
- (2011) Ángeles Ruiz-Extremera et al. HEPATOLOGY
- Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?
- (2010) Martin Lagging et al. JOURNAL OF HEPATOLOGY
- SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C
- (2009) Giada Sebastiani et al. HEPATOLOGY
- The history of the “natural history” of hepatitis C (1968-2009)
- (2009) Leonard B. Seeff LIVER INTERNATIONAL
- Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
- (2008) Martin Lagging et al. HEPATOLOGY
- Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection
- (2008) Martin Lagging et al. HEPATOLOGY
- A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
- (2007) Johan Westin et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started